Seaport Therapeutics, Inc. (SPTX)
NASDAQ: SPTX · Real-Time Price · USD
19.55
+0.58 (3.06%)
Jun 24, 2026, 2:05 PM EDT - Market open
Seaport Therapeutics Employees
Seaport Therapeutics had 58 employees as of March 31, 2026. The number of employees did not change since the number was last reported on December 31, 2025.
Employees
58
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,502,828
Market Cap
1.05B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 58 | 0 | - |
| Dec 31, 2025 | 58 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| MeiraGTx Holdings | 409 |
| Pharming Group | 407 |
| Xencor | 260 |
| DBV Technologies | 161 |
| ARS Pharmaceuticals | 159 |
| Sana Biotechnology | 142 |
| Cullinan Therapeutics | 109 |
| Jade Biosciences | 55 |
SPTX News
- 14 days ago - Seaport Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 15 days ago - PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers - Business Wire
- 16 days ago - Seaport Therapeutics reports Q1 EPS ($10.34) vs. ($5.65) last year - TheFly
- 16 days ago - Seaport Therapeutics sees cash runway into 2029 - TheFly
- 16 days ago - Seaport announces data from MAD part of Phase 1 trial of GlyphAgo - TheFly
- 16 days ago - Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress - Business Wire
- 16 days ago - Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers - Business Wire
- 16 days ago - Seaport Therapeutics Earnings release: Q1 2026 - Filings